TITLE

Biotech Equity, M&A Activity Set to Surge

AUTHOR(S)
Abrams, Sandra Lea
PUB. DATE
January 2005
SOURCE
Investment Dealers' Digest;1/31/2005, Vol. 71 Issue 4, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the booming of biotechnology company activity in equity markets. In the biotech sector, from a deal flow perspective, there are a lot of companies across the board that are making plans in terms of M&A activity, in terms of follow-ons and most definitely in terms of IPOs. If a biotech equity wave does occur, it will be driven by different factors than those fueling a typical healthcare sector boom. Bankers cautioned that a biotech sector upswing is not a guaranteed event, as concerns about the sector's future still linger. Biotechs, as opposed to healthcare service companies are not driven by revenues and cash flow.
ACCESSION #
15894468

 

Related Articles

  • Financing the French future. Pouletty, Phillipe // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p50 

    The article argues that a new financial model is required if the French biotechnology sector is to compete internationally. By allowing small and medium enterprises in France to finance their international growth using the French-European stock market and by stimulating investor interest through...

  • VC Investments in Biotech Dip 12%, But Deal Size Doubles. Robbins-Roth, Cynthia // BioWorld Today;10/5/2011, Vol. 22 Issue 193, p1 

    The article reports that investments in biotech companies for the first nine months of 2011 dropped 12% from last year. It mentions that despite the fall in venture capital, 72 companies were able to raise 1.5 billion dollars which is still a substantial amount. The investment trends in Series A...

  • Biotech buybacks–good or bad? Jacobs, Tom // Nature Biotechnology;Oct2006, Vol. 24 Issue 10, p1207 

    The article offers tips on how to handle repurchasing or buying back of stocks of a company operating in the biotechnology industry. A buyback is neither good nor bad by definition, but may be smart, dumb or bordering on fraudulent. In a buyback, the company takes cash from the company checking...

  • Series A And B Rounds Up As Early Stage Model Evolves. Morrison, Trista // BioWorld Today;5/1/2007, Vol. 18 Issue 85, p1 

    The article reports on the flow of venture capital money into and through the biotechnology industry for the first quarter of 2007. According to data from "BioWorld Financial Watch" and BioWorld Snapshots, of the $2.1 billion in venture capital invested in global biotechnology companies,...

  • The Mid-Atlantic Region. Jones, Dennis; Jones, Sandi // Export Wise;Summer2007, p24 

    The article discusses the opportunities for Canadian exporters in establishing business in the Mid-Atlantic region of the U.S. It cites that the region is a home of the country's capital, a major defence-market and a key region for research and development in knowledge-intensive industries...

  • Cash-Strapped Biotechs Seeking Safety in M&A. Brosky, John // BioWorld International;11/19/2008, Vol. 13 Issue 47, p3 

    The article focuses on the opening plenary session at the BIO-Europe 2008 event. According to John Craighead, head of business development with BIO, the volatile stock market is sending mixed signals, but the message is alliances are now essential for capital formation among biotechnology...

  • Korean biotechs seize opportunity to list on public markets. Louët, Sabine // Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1189 

    The article reports that cash-starved biotech companies in Korea are hoping that changes in the listing rules for the Korean Stock Exchange introduced earlier this year will allow them to float. Three Korean companies are preparing to list on the KOSDAQ market division of Korea's exchange within...

  • PURSUING BIOTECHNOLOGY. Lewis, Nicole // Black Enterprise;Aug2006, Vol. 37 Issue 1, p70 

    The article focuses on business opportunities in the field of biotechnology, which is the application of scientific and engineering principles to manipulate life forms to provide products for human use. The U.S. Biotechnology Industry Organization has noted that U.S. healthcare biotechnology...

  • Public biotech 2006–the numbers. Lähteenmäki, Riku; Lawrence, Stacy // Nature Biotechnology;Jul2007, Vol. 25 Issue 7, p729 

    The article presents a survey which identifies the increase in revenue and research and development expenditure of biotechnology companies that were publicly traded on stock exchanges in 2006. It was noted that the industry's total biotechnology financing reached 48.3 billion dollars. In...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics